NAFLD 和肝移植 : 疾病负担 ,当前的管理和未来的挑战。
关键词: CKD, chronic kidney disease CNI, calcineurin inhibitors DM, diabetes mellitus DPP-4, dipeptidyl peptidase-4 ELTR, European Liver Transplant Registry ESLD, end-stage liver disease GLP1 RAs, glucagon-like peptide-1 receptor agonists Graft survival HCC, hepatocellular carcinoma HR, hazard ratio Hypertension IRR, incidence rate ratio Immunosuppressant LT, liver transplant MAFLD, metabolic dysfunction-associated fatty liver disease Metabolic complication NAFLD, non-alcoholic fatty liver disease NASH, non-alcoholic steatohepatitis New-onset diabetes after transplantation Non-alcoholic fatty liver disease Non-alcoholic steatohepatitis OR, odds ratio Obesity Patient survival SGLT2, sodium-glucose co-transporter-2 Solid organ transplantation UNOS, United Network for Organ Sharing mTORi, mammalian target of rapamycin inhibitors
来 源:
DOI:10.1016/j.jhepr.2020.100192
PDF(Sci-hub)
PDF(Pubmed)